Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acids and salts thereof
Reexamination Certificate
2011-01-25
2011-01-25
Witherspoon, Sikarl A (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acids and salts thereof
C562S496000, C514S521000, C514S559000, C514S561000
Reexamination Certificate
active
07875744
ABSTRACT:
The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.
REFERENCES:
patent: 4125732 (1978-11-01), McEvoy et al.
patent: 5360909 (1994-11-01), Igarashi et al.
patent: 7301050 (2007-11-01), Kuo et al.
patent: 7425649 (2008-09-01), Kuo et al.
patent: 7598292 (2009-10-01), Kuo et al.
patent: 7598416 (2009-10-01), Kuo et al.
patent: 7635718 (2009-12-01), Kuo et al.
patent: 2003/0225158 (2003-12-01), Auerbach et al.
patent: 2006/0058393 (2006-03-01), DeAngelis et al.
patent: 2010/0004470 (2010-01-01), Kuo et al.
patent: 10195057 (1998-07-01), None
patent: WO 97/28115 (1997-08-01), None
patent: WO 02/062774 (2002-08-01), None
patent: WO 02/100813 (2002-12-01), None
Braissant et al., “Differential Expression of Peroxisome Proliferator-Activated Receptors (PPARs): Tissue Distribution of PPAR-α, -β, and -γ in the Adult Rat*.”, Endrocrinology, 1996, vol. 137(1), pp. 354-366.
Boden, G., “Free Fatty Acids, Insulin Resistance, and Type 2 Diabetes Mellitus.”, Proceedings of the Association of American Physicians, 1991, vol. 111(3), pp. 241-248.
Leibowitz et al., “Activation of PPARδ alters lipid metabolism in db/db mice.”, FEBS Lett., 2000, vol. 473(3), pp. 333-336.
Shi et al., “The peroxisome proliferator-activated receptor ,an integrator of transcriptional repression and nuclear receptor signaling.”, Proc Natl. Acad. Sci., 2002, vol. 99(5), pp. 2613-2618, USA.
Auboeuf et al., “Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator-Activated Receptors and Liver X Receptor-α in Humans.”, Diabetes, 1997, vol. 46(8), pp. 1319-1327.
Lawn et al., “The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway.”, J. Clin. Investigation, 1999, vol. 104(8), pp. R25-R31.
Berge et al., “Pharmaceutical Salts.”, J. Pharm. Sci., 1977, vol. 66(1), pp. 1-19.
Oliver et al., “A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport.”, PNAS, 2001, vol. 98(9), pp. 5306-5311.
PCT International Search Report, dated Jun. 3, 2006 for PCT Appin.No. PCT/US2005/032938 which relates to U.S. Appl. No. 11/226,645, filed Sep. 14, 2005, now US Patent 7,425,649.
Written Opinion of the International Searching Authority for PCT Application No. PCT/US2005/032938.
DeAngelis Alan
Demarest Keith
Kuo Gee-Hong
Pelton Patricia
Wang Aihua
Janssen Pharmaceutica NV
Witherspoon Sikarl A
LandOfFree
4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2621527